Symbols

GH

Guardant Health·NASDAQ

--(--)

Signals Analysis

Bullish signal 5

Bearish signal 1

Consensus Rating "Strong Buy"

Ample Liquidity

High Gross Profit Margin

Revenue Beats Expectation

EPS Beats Expectation

Hanging Man

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About GH

Guardant Health, Inc.

A leading precision oncology company that provides non-invasive cancer testing and analytics

Industry

Biological Technology

Established Date

Listing Date

10/04/2018

Exchange

NASDAQ Stock Exchange

Full-time Employees

2,490

Fiscal Year Ends

12-31

Website

www.guardanthealth.com

Security Type

Common stock

Office address

3100 Hanover Street, Palo Alto, California, 94304

Business

Introduction

Guardant Health, Inc., was incorporated in Delaware in December 2011. The company is a leading precision oncology company dedicated to helping the world conquer cancer through the use of its proprietary blood tests, extensive datasets and advanced analysis. They revolutionize patient care by providing key insights into disease drivers using advanced blood and tissue testing, real-world data, and artificial intelligence analysis. Their tests help improve treatment outcomes at all stages, including early cancer screening, early cancer recurrence monitoring, and treatment option selection for patients with advanced cancer.

Company Financials

EPS

GH has released its 2025 Q4 earnings. EPS was reported at -0.5, versus the expected -0.77, beating expectations. The chart below visualizes how GH has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

GH has released its 2025 Q4 earnings report, with revenue of 281.27M, reflecting a YoY change of 39.37%, and net profit of -128.49M, showing a YoY change of -15.75%. The Sankey diagram below clearly presents GH's revenue sources and cost distribution.